| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Acid/Base and Electrolyte Disorders |
,**
* Department of Internal Medicine, Jolimont/Tubize-Nivelles Hospital, Tubize, Research Unit for the Study of Hydromineral Metabolism and ** Department of General Internal Medicine, Erasmus University Hospital, Free University of Brussels, Brussels, and Department of Internal Medicine, Regional Hospital Center of Citadelle, Liege, Belgium; Nephrology, Department of Medicine, University Medical Center Care Gustav Carus, Dresden, Germany; || Szent Imre Kórház és Rendelöintézet I, Belgyógyászati Osztály, Budapest, Hungary; ¶ Department of Intensive Care Unit, Raymond Poincare Hospital, Garches, France; and Clinical Development, Sanofi-Aventis, Malvern, Pennsylvania
Address correspondence to: Dr. Alain Soupart, Research Unit for the Study of Hydromineral Metabolism, Department of General Internal Medicine, Free University of Brussels, Hôpital Erasme, 808, route de Lennik, 1070 Brussels, Belgium. Phone: +322-555-4960; Fax: +322-555-3211; E-mail: alainsoupart{at}swing.be
The effects of satavaptan (SR121463B), a novel long-acting orally active vasopressin V2-receptor antagonist, were investigated in patients with the syndrome of inappropriate antidiuretic hormone secretion (SIADH). In the first part of this randomized, double-blind study, 34 patients first were treated with satavaptan (versus placebo) for up to 5 d and then during 23 d of open-label dosage-adjustment period. In the second part of the study, long-term efficacy and safety of satavaptan was assessed in an open-label trial during at least 12 mo. Mean (±SD) serum sodium (SNa) levels before treatment were 127 ± 2 mmol/L (placebo, n = 8), 125 ± 6 mmol/L (25 mg, n = 14), and 127 ± 5 mmol/L (50 mg, n = 12). Responders (patients SNa levels normalized or increased by at least 5 mmol/L from baseline during the double-blind period) were 79% in the 25-mg group (SNa 136 ± 3 mmol/L; P = 0.006), 83% in the 50-mg group (SNa 140 ± 6 mmol/L; P = 0.005), and 13% in the placebo group (SNa 130 ± 5 mmol/L). No drug-related serious adverse events were recorded. During the long-term treatment, 15 of 18 enrolled patients achieved 6 mo and 10 achieved 12 mo of treatment. The SNa response was maintained during this time with a good tolerance. The new oral vasopressin V2-receptor antagonist satavaptan adequately corrects mild or moderate hyponatremia in patients with SIADH and has a good safety profile.
This article has been cited by other articles:
|
|
 |
|
  P. Gross, T. Marczewski, and K. Herbrig The vaptans ante portas: a status report Nephrol. Dial. Transplant., May 1, 2009; 24(5): 1371 - 1373. [Full Text] [PDF]
|
|
|
|
 |
|
 W. Fenske, S. Stork, A. Blechschmidt, S. G. K. Maier, N. G. Morgenthaler, and B. Allolio Copeptin in the Differential Diagnosis of Hyponatremia J. Clin. Endocrinol. Metab., January 1, 2009; 94(1): 123 - 129. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. W. Lehrich and A. Greenberg When Is It Appropriate to Use Vasopressin Receptor Antagonists? J. Am. Soc. Nephrol., June 1, 2008; 19(6): 1054 - 1058. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Whitmire Nutrition-Focused Evaluation and Management of Dysnatremias Nutr Clin Pract, April 1, 2008; 23(2): 108 - 121. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
